 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study |
| Yasuo Suzuki, Mitsuo Iida, Hiroaki Ito, Isamu Saida, Toshifumi Hibi |
|
Intest Res. 2016;14(1):50-59. Published online January 26, 2016 DOI: https://doi.org/10.5217/ir.2016.14.1.50 |
|
Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study Intestinal Research. 2016;14(1):50  Safety and Efficacy of a New 3.3g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Yearbook of Gastroenterology. 2009;2009:110-111 Mo1786 A Multi-Center, Double-Blind, Placebo Controlled, Parallel Group, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of the S1P Receptor Modulator Krp203 in Subjects With Moderately Active Refractory Ulcerative Colitis Gastroenterology. 2016;150(4):S775-S776 Su1125 Long-Term Efficacy of a pH-Dependent Release Mesalamine Formulation, Asacol in Patients With Ulcerative Colitis Who Showed Inadequate Response to a Time-Dependent Release Mesalamine Formulation, Pentasa: A Prospective Study Gastroenterology. 2014;146(5):S-381-S-382 Safety and Efficacy of a New 3.3 g b.i.d. Tablet Formulation in Patients With Mild-to-Moderately-Active Ulcerative Colitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study The American Journal of Gastroenterology. 2009;104(6):1452-1459 Su1916 RAPID HISTO-ENDOSCOPIC MUCOSAL HEALING WITH (HIGH DOSE) MESALAMINE IN ACTIVE MILD-MODERATE ULCERATIVE COLITIS: POSTHOC ANALYSIS OF POOLED DATA FROM 4 DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, RANDOMIZED TRIALS Gastroenterology. 2020;158(6):S-701 Sa1112 Long-Term Efficacy of a pH-Dependent Release Mesalamine Formulation, Asacol in Patients With Ulcerative Colitis Who Showed Inadequate Response to a Time- Dependent Release Mesalamine Formulation, Pentasa: A Prospective study Gastroenterology. 2013;144(5):S-205 Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial . 2021; Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial . 2020; 83 Efficacy and Tolerability of a Once Daily Treatment with Budesonide Capsules Versus Mesalamine Granules for the Treatment of Active Ulcerative Colitis: A Randomized, Double-Blind, Double-Dummy, Multicenter Study Gastroenterology. 2009;136(5):A-15 |
